Bioventus (BVS) Asset Writedowns and Impairment (2020 - 2026)
Bioventus' (BVS) quarterly Asset Writedowns and Impairment came in at $230000.0 in Q1 2026, down 64.62% YoY from $650000.0 in Q1 2025, and up 124.36% on a QoQ basis from -$944000.0 in Q4 2025.
Bioventus (BVS) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
Bioventus (BVS) has 7 years of Asset Writedowns and Impairment data on file, last reported at $230000.0 in Q1 2026.
- Quarterly Asset Writedowns and Impairment fell 64.62% year-over-year to $230000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$420000.0 (down 101.21% YoY) and the FY2024 annual result came in at -$434000.0, down 100.55% from the prior year.
- Asset Writedowns and Impairment advanced to $230000.0 in Q1 2026, from -$944000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $78.6 million in Q2 2023 to a low of -$976000.0 in Q1 2024.
- A 5-year average of $9.6 million and a median of $650000.0 in 2025 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment soared 6724.22% — and 2025, when it tumbled 627.37%.
- Tracing BVS's Asset Writedowns and Impairment over 5 years: stood at $10.3 million in 2022, then surged by 664.37% to $78.6 million in 2023, then sank by 99.77% to $179000.0 in 2024, then plunged by 627.37% to -$944000.0 in 2025, then jumped by 124.36% to $230000.0 in 2026.
- The last three Asset Writedowns and Impairment figures came in at $230000.0 (Q1 2026), -$944000.0 (Q4 2025), and $101000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn |
| 10 | Bioventus | 972.56 Mn | 943.11 Mn | 105.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | -85,000.00 |
| Jun 27, 2026 | -85,000.00 |
| Mar 28, 2026 | 230,000.00 |
| Mar 28, 2026 | 230,000.00 |
| Dec 31, 2025 | -944,000.00 |
| Dec 31, 2025 | -944,000.00 |
| Sep 27, 2025 | 101,000.00 |
| Sep 27, 2025 | 101,000.00 |
| Jun 28, 2025 | 193,000.00 |
| Jun 28, 2025 | 193,000.00 |
| Mar 29, 2025 | 650,000.00 |
| Mar 29, 2025 | 650,000.00 |
| Dec 31, 2024 | 179,000.00 |
| Dec 31, 2024 | 179,000.00 |
| Sep 28, 2024 | 2.03 Mn |
| Sep 28, 2024 | 2.03 Mn |
| Jun 29, 2024 | 31.87 Mn |
| Jun 29, 2024 | 31.87 Mn |
| Mar 30, 2024 | -976,000.00 |
| Mar 30, 2024 | -976,000.00 |